University of Warwick research shows prostate cancer patients who received the chemotherapy drug docetaxel with standard hormone therapy lived ten months longer on average

New research led by the University of Warwick shows newly diagnosed advanced prostate cancer patients who received the chemotherapy drug docetaxel with standard hormone therapy lived ten months longer on average, compared to those who received standard therapy alone. COVENTRY, … Read the full press release →